<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="molecules-25-03846-t004" orientation="portrait" position="float">
 <object-id pub-id-type="pii">molecules-25-03846-t004_Table 4</object-id>
 <label>Table 4</label>
 <caption>
  <p>The roles of aromatic polyketides with limited distribution in human disease.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Medicinal Application 
     <sup>a</sup>
    </th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mode of Action</th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dose and Mode of Application 
     <sup>a</sup>
    </th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Is There Clinical Evidence That It Has, or Will Have, Therapeutic Benefit in Humans? 
     <sup>a</sup>
    </th>
    <th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Comment 
     <sup>a</sup>
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">flavopiridol</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">cancer</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">cyclin-dependent kinase inhibitor</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">60–100 mg mg/m
     <sup>2</sup> IV
    </td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Yes [
     <xref rid="B160-molecules-25-03846" ref-type="bibr">160</xref>]
    </td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Replaced by more efficient agents</td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">resveratrol</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">inflammatory conditions, CVD, cancer</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">remains to be established</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">1.4–4.2 mg/kg bw 
     <sup>b</sup> orally in the form of dietary supplements
    </td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Not enough data [
     <xref rid="B92-molecules-25-03846" ref-type="bibr">92</xref>,
     <xref rid="B100-molecules-25-03846" ref-type="bibr">100</xref>]
    </td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Still not accepted as a medicinal agent</td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">combretastatin A-4 posphate</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">cancer</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">vascular disrupting agent; mitotic poison</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">5–120 mg/m
     <sup>2</sup> IV
    </td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Yes [
     <xref rid="B161-molecules-25-03846" ref-type="bibr">161</xref>]
    </td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Still in clinical development</td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">kava and kavalactones</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">anxiolytic</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">interaction with GABA, glutamate, dopamine, serotonin and cannabinoid systems</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">1–3.5 mg/kg bw 
     <sup>b</sup> of kavalactones orally in the form of standardized kava root extract
    </td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Yes [
     <xref rid="B116-molecules-25-03846" ref-type="bibr">116</xref>]
    </td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Due to severe hepatotoxicity no longer marketed in many countries</td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">curcumin</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">inflammatory conditions, cancer</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">remains to be established</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">7.14–14.2 mg/kg bw 
     <sup>b</sup> of turmeric extract orally in the form of dietary supplements
    </td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Despite large number of clinical trials, no evidence have been observed as of yet [
     <xref rid="B127-molecules-25-03846" ref-type="bibr">127</xref>]
    </td>
    <td align="center" valign="middle" rowspan="1" colspan="1">There are few reports of deaths after administration of IV curcumin</td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">gingerols and shogaols</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">kinetosis, migraine, headache, rheumatism</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">presumably via interaction with serotonin receptors</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">3.5–14.2 mg/kg bw 
     <sup>b</sup> of ginger powder orally
    </td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Limited data in humans [
     <xref rid="B132-molecules-25-03846" ref-type="bibr">132</xref>]
    </td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Ginger contains other compounds which may also contribute to observed effects</td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">silymarin</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">liver damage and injury</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">inhibition of toxin absorption</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">2–10.2 mg/kg bw 
     <sup>b</sup> of silymarin orally in the form of standardized 
     <italic>Silybum</italic> seed extract
     <break/>20 mg/kg bw 
     <sup>b</sup> IV 
     <sup>c</sup>
    </td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Yes, e.g., IV form of silymarin
     <sup>c</sup> is used clinically in treatment of mushroom poisoning. Oral products (e.g 
     <italic>Silybum</italic> infusions) seems to have low effectivity [
     <xref rid="B138-molecules-25-03846" ref-type="bibr">138</xref>]
    </td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Orally active derivatives would perhaps expand the therapeutic applicability</td>
   </tr>
   <tr>
    <td align="center" valign="middle" rowspan="1" colspan="1">daidzein/genistein</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">menopause symptoms</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">interaction with oestrogen receptors</td>
    <td align="center" valign="middle" rowspan="1" colspan="1">0.05 - 0.7 mg/kg bw 
     <sup>b</sup> of isoflavonoids orally in the form of standardized soy extracts
    </td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Conflicting results are observed, more studies are required [
     <xref rid="B144-molecules-25-03846" ref-type="bibr">144</xref>]
    </td>
    <td align="center" valign="middle" rowspan="1" colspan="1">Oestrogens are planar molecules, whereas isoflavonoids not–this feature may impede their interaction with oestrogenic receptors</td>
   </tr>
   <tr>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">phenoxodiol</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">cancer</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">inhibition of NADH oxidase</td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">up to 27 mg/kg bw 
     <sup>b</sup> IV
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes [
     <xref rid="B162-molecules-25-03846" ref-type="bibr">162</xref>]
    </td>
    <td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">More efficient agents are in clinical development</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>
    <sup>a</sup> CVD = cardiovascular disorders, IV = intravenous application; 
    <sup>b</sup> given that the average body weight of an adult human is 70 kg; 
    <sup>c</sup> silymarin in the form of bis-hemisuccinate (Legalon
    <sup>®</sup>SIL).
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
